Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

High Myopia: Extended and Longterm Observation of Pathologic Myopia Patients With the Risk for Developing a Myopic Choroidal Neovascularization (CNV)

Completed

Conditions: Pathologic Myopia

Interventions: Procedure: Observation & Diagnosis

First Posted Date: 2017-03-03

Last Posted Date: 2019-07-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 153

Registration Number: NCT03070717

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis

Phase 3

Completed

Conditions: Plaque Psoriasis

Interventions: Drug: Placebo
Drug: Secukinumab 150 mg s.c.
Drug: Secukinumab 300 mg s.c.

First Posted Date: 2017-02-28

Last Posted Date: 2019-12-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 543

Registration Number: NCT03066609

Locations: 🇹🇷
Novartis Investigative Site, Pendik / Istanbul, Turkey

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

Phase 3

Completed

Conditions: Heart Failure With Preserved Ejection Fraction

Interventions: Drug: sacubitril/valsartan
Drug: Enalapril
Drug: Placebo to match enalapril
Drug: Valsartan
Drug: Placebo to match valsartan
Drug: Placebo to match sacubitril/valsartan

First Posted Date: 2017-02-28

Last Posted Date: 2021-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2572

Registration Number: NCT03066804

Locations: 🇬🇧
Novartis Investigative Site, York, United Kingdom

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Phase 1

Completed

Conditions: Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Bone Marrow Diseases
Hematologic Diseases
Chronic Myelomonocytic Leukemia

Interventions: Drug: MBG453
Drug: Decitabine
Drug: PDR001
Drug: Azacitidine

First Posted Date: 2017-02-28

Last Posted Date: 2025-05-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 241

Registration Number: NCT03066648

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Oregon Health Sciences University Main Center, Portland, Oregon, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 1 locations

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Phase 1

Terminated

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: PDR001
Drug: Cisplatin
Drug: Carboplatin
Drug: Gemcitabine
Drug: Pemetrexed
Drug: Paclitaxel
Drug: Canakinumab

First Posted Date: 2017-02-27

Last Posted Date: 2022-08-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT03064854

Locations: 🇺🇸
UCLA Santa Monica Hematology / Oncology SC-2, Santa Monica, California, United States
🇺🇸
Henry Ford Health System SC, Detroit, Michigan, United States
🇺🇸
Stanford Cancer Center SC, Stanford, California, United States

and more 3 locations

Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: QVM149 150/50/80 μg o.d.
Drug: QVM149 150/50/160 μg o.d.
Drug: salmeterol/fluticasone FDC 50/500 μg b.i.d.

First Posted Date: 2017-02-24

Last Posted Date: 2021-10-04

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 116

Registration Number: NCT03063086

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

Phase 2

Completed

Conditions: Atherosclerotic Cardiovascular Disease
Symptomatic Atherosclerosis
Type2 Diabetes
Familial Hypercholesterolemia

Interventions: Drug: Inclisiran
Drug: Evolocumab

First Posted Date: 2017-02-23

Last Posted Date: 2023-03-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT03060577

Locations: 🇬🇧
Novartis Investigative Site, Worcester, United Kingdom

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Alpelisib
Drug: Fulvestrant
Drug: Letrozole
Drug: Goserelin
Drug: Leuprolide

First Posted Date: 2017-02-17

Last Posted Date: 2025-01-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 379

Registration Number: NCT03056755

Locations: 🇺🇸
Kaiser Permanente Medical Group, Anaheim, California, United States
🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
University of Louisville James Graham Brown Cancer Center, Louisville, Kentucky, United States

and more 23 locations

Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients

Phase 4

Completed

Conditions: Plaque Psoriasis

Interventions: Biological: Placebo
Biological: Secukinumab

First Posted Date: 2017-02-16

Last Posted Date: 2023-03-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 102

Registration Number: NCT03055494

Locations: 🇺🇸
Novartis Investigative Site, Norfolk, Virginia, United States

Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment

Phase 3

Terminated

Conditions: Asthma

Interventions: Drug: QAW039 150 mg
Drug: QAW039 450 mg
Drug: Placebo

First Posted Date: 2017-02-14

Last Posted Date: 2020-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2538

Registration Number: NCT03052517

Locations: 🇬🇧
Novartis Investigative Site, Leicester, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy